Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (November 2020)

32 slides from Sorrento Therapeutics's investor presentation, Nov 17, 2020

Slide 2: Forward-looking statements
Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc . (the “Company” or “Sorrento”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, are or may be considered
Slide 3: About the Company
About the COMPANY • Funded and Operational in 2009 • NASDAQ: SRNE • HQ in San Diego, CA 350 Employees including 100+ PhDs & MDs 300,000 SF Research and cGMP Manufacturing Facilities • 5 cGMP Manufacturing Sites (4 USA, 1 China) mAbs, ADC, Plasmid DNA, Cell Therapies, Oncolytic Viruses, and Fill & Fi
Slide 4: Programs: Immuno-Oncology, Pain Management, COVID-19
Immuno - Oncology Non - Opioid Pain Management © 2020 Sorrento Therapeutics, Inc. All Rights Reserved 4 COVID - 19 COVI - GUARD COVI - AMG SP - 102 DAR - T Abivertinib COVI - DROPS COVI - STIX RTX ZTlido ®
Slide 7: COVID Programs
7 COVID - 19 Programs Pre - infection Diagnosis Treatment (ascending disease severity) COVI - GeneMAb ™ COVI - TRACE™ COVI - STICK™ COVI - TRACK™ COVI - DROPS™ (STI - 2099 ) COVI - AMG™ (STI - 2020) COVI - GUARD™ (STI - 1499) Abivertinib (STI - 5656) aMSC (STI - 8282) SARS - CoV - 2 STI - 2099 STI -
Slide 9: COVI-STIX Virus Antigen Test
» Simple: Eliminates laborious extraction step and is designed for potential point - of - care (moderately trained technicians) or at - home use » Accurate: Rapid and highly sensitive platinum colloid - based lateral flow immunoassay to detect SAR - CoV - 2 virus antigens (98% sensitivity, 100% spec
Slide 10: COVI-TRACE Rapid Point-of-Care RNA Test
COVI - TRACE™ Rapid Point - of - Care SARS - CoV - 2 Virus RNA Test » COVI - TRACE: High Sensitivity and Specificity* » Simple Process: Saliva sample without RNA extraction and no need for complex lab equipment » Colorimetric Reading: red = negative, yellow = positive » In - Field and On - Site Resu
Slide 11: COVI-TRACK Antibody Test
COVI - TRACK™ Antibody Test Indicating Recent Infection » This rapid (< 8 minutes) SARS - CoV - 2 IgG/IgM antibody test kit is intended for use initially in clinical laboratories and point of care to quickly identify individuals with anti - SARS - CoV - 2 antibodies present » Enable confirmation of
Slide 14: COVI-GeneMAb (STI-8472)
14 Treatment by Intramuscular Injection of STI - 2020 - mAb - encoding DNA Plasmid COVI - GeneMAb™ (STI - 8472) (STI - 2020 - encoded by DNA Plasmid) » STI - 2020 - encoded GeneMAb is in development for intramuscular administration to protect against the SARS - CoV - 2 virus and its variant strains
Slide 15: COVI-GUARD (STI-1499)
COVI - GUARD™ (STI - 1499)* 15 » A potent Anti - SARS - CoV - 2 antibody, COVI - GUARD demonstrated complete neutralization of infection in African green monkey kidney epithelial cells (VERO/E6 cells) in vitro at low concentrations. COVI - GUARD was similarly potent in preclinical studies for neutra
Slide 16: COVI-AMG (STI-2020)
COVI - AMG™ (STI - 2020)* 16 » COVI - AMG engineered for ultra - high potency, with an expected effective dose in humans suitable for IV push administration in an outpatient setting » COVI - AMG administered IV immediately following infection or 12 hours post - infection protects SARS - CoV - 2 - in
Slide 17: COVI-DROPS (STI-2099)
COVI - DROPS™ (STI - 2099)* 17 » COVI - DROPS is an intranasal formulation of the highly potent SARS - CoV - 2 neutralizing antibody STI - 2020 » A single intranasal administration of COVI - DROPS prevented disease - associated weight loss in treated hamsters. The impact of the treatment was observe
Slide 18: Abivertinib (STI-5656): Severe COVID-19 Pulmonary Symptoms
18 » STI - 5656 is in Phase 2 clinical studies as a treatment of severe COVID - 19 symptoms (ARDS) » STI - 5656 has been shown to be safe and well tolerated at doses up to 600 mg daily in the treatment of non - small cell lung cancer and B cell lymphomas. The dose in the COVID - 19 studies is 100 mg
Slide 19: aMSC (STI-8282) for Acute Lung Damage
19 » aMSC (STI - 8282): Allogeneic culture - expanded adipose - derived Mesenchymal stem cells for the rescue of patients with lung damage and acute respiratory distress syndrome (ARDS) due to COVID - 19 » Preclinical studies have demonstrated that aMSCs may produce a reduction in lung inflammation,
Slide 21: Lead Marketed Product: ZTlido 1.8%
Lead Marketed Product: ZTlido® 1.8% FDA approved for relief of pain associated with PHN Properties ZTlido® 1.8% Lidoderm® 5% Bioavailability ~45% ~3 + 2% Weight 2 g 14 g Thickness 0.8 mm 1.7 mm Lidocaine content 36 mg 700 mg Adhesive Non - aqueous Water - based ® • ZTlido sales exhibited continuous
Slide 22: SP-102: Pivotal Phase 3 Trial
SP - 102: Pivotal Phase 3 trial - Over 90% Enrolled If Approved Could be the First Steroid Formulation with an FDA - Approved Label to Treat Lumbar Radicular/Sciatica Pain Potent non - particulate steroid (injectable dexamethasone sodium phosphate gel) ᪵ Viscous g el formulation for extended local r
Slide 23: Resiniferatoxin (RTX)
Resiniferatoxin (RTX) 23 © 2020 Sorrento Therapeutics, Inc. All Rights Reserved Resiniferatoxin is a potent agonist of the transient receptor potential cation channel sub - family V member 1 (TRPV 1 ) predominantly found in a subpopulation of small C and A delta sensory neurons most often involved i
Slide 24: Clinical Studies Status
CLINICAL STUDIES STATUS (2020 COMPLETED ENROLLMENT) OA KNEE PAIN Phase 1b double - blinded, placebo - controlled study to assess the safety and preliminary efficacy of intra - articular administration of Resiniferatoxin or saline control (as placebo group) for the treatment of moderate to severe pai
Slide 25: Study Results – Epidural Admin (Cancer Pain)
Study Results – Epidural Admin (Cancer Pain) – Study Closed. INTRACTABLE CANCER PAIN A Multicenter, Open - Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer www.clinica
Slide 26: Study Results – Intra-articular Admin (OA Knee Pain)
Study Results – Intra articular admin (OA Knee Pain). Study Closed. OA KNEE PAIN Phase 1b double - blinded, placebo - controlled study to assess the safety and preliminary efficacy of intra - articular administration of Resiniferatoxin or saline control (as placebo group) for the treatment of modera
Slide 31: Abivertinib (STI-5656): NSCLC and B Cell Lymphomas
31 © 2020 Sorrento Therapeutics, Inc. All Rights Reserved ABIVERTINIB (STI - 5656): NSCLC and B Cell Lymphomas » Abivertinib maleate (STI - 5656) is a potent, small molecule third - generation tyrosine kinase inhibitor (TKI) of mutant epidermal growth factor receptor (EGFR) and Bruton tyrosine kinas
Slide 32: Executive Team
sorrento Executive Team

Sorrento Therapeutics — Investor Presentation (November 2020) on 6ix

Sorrento Therapeutics — Investor Presentation (November 2020)

Slide 1: Saving Life Medicine

Slide 2: Forward-looking statements

Slide 3: About the Company

Slide 4: Programs: Immuno-Oncology, Pain Management, COVID-19

Slide 5: COVID Programs

Slide 6: Detect Early and Treat Timely

Slide 7: COVID Programs

Slide 8: COVID Diagnostics

Slide 9: COVI-STIX Virus Antigen Test

Slide 10: COVI-TRACE Rapid Point-of-Care RNA Test

Slide 11: COVI-TRACK Antibody Test

Slide 12: COVID Therapeutics

Slide 13: G-MAB Library for Neutralizing Antibody Discovery

Slide 14: COVI-GeneMAb (STI-8472)

Slide 15: COVI-GUARD (STI-1499)

Slide 16: COVI-AMG (STI-2020)

Slide 17: COVI-DROPS (STI-2099)

Slide 18: Abivertinib (STI-5656): Severe COVID-19 Pulmonary Symptoms

Slide 19: aMSC (STI-8282) for Acute Lung Damage

Slide 20: Non-opioid Pain Programs

Slide 21: Lead Marketed Product: ZTlido 1.8%

Slide 22: SP-102: Pivotal Phase 3 Trial

Slide 23: Resiniferatoxin (RTX)

Slide 24: Clinical Studies Status

Slide 25: Study Results – Epidural Admin (Cancer Pain)

Slide 26: Study Results – Intra-articular Admin (OA Knee Pain)

Slide 27: Persistence of Effect (OA Knee Pain)

Slide 28: Immuno-Oncology Programs

Slide 29: Sorrento Immuno-Oncology Toolbox

Slide 30: Core Oncology Pipeline Continues to Progress

Slide 31: Abivertinib (STI-5656): NSCLC and B Cell Lymphomas

Slide 32: Executive Team